We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

127 hedge funds and large institutions have $418M invested in Intra-Cellular Therapies Inc. in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 42 increasing their positions, 46 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

319% more call options, than puts

Call options by funds: $49.3M | Put options by funds: $11.8M

9% less repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 46

3% less funds holding

Funds holding: 131 → 127 (-4)

17% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 18

49% less capital invested

Capital invested by funds: $827M → $418M (-$409M)

Holders
127
Holders Change
-4
Holders Change %
-3.05%
% of All Funds
2.83%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
42
Reduced
46
Closed
18
Calls
$49.3M
Puts
$11.8M
Net Calls
+$37.6M
Net Calls Change
+$13.9M

Top Buyers

Rank Fund Capital Flow
1
SC
Samlyn Capital
New York
+$7.99M
2
Millennium Management
Millennium Management
New York
+$6.16M
3
GAI
General American Investors
New York
+$4.84M
4
Citadel Advisors
Citadel Advisors
Florida
+$4.36M
5
Two Sigma Investments
Two Sigma Investments
New York
+$3.11M

Top Sellers

Rank Fund Capital Flow
1
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$11M
2
DFO
Duquesne Family Office
New York
-$6.45M
3
Bank of America
Bank of America
North Carolina
-$6.01M
4
CCP
Clough Capital Partners
Massachusetts
-$5.93M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$5.39M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$93.5M +$43.7K +2,708 +0%
BlackRock
2
BlackRock
New York
$45.6M +$1.23M +76,356 +2%
Vanguard Group
3
Vanguard Group
Pennsylvania
$44.8M -$159K -9,862 -0.3%
BB
4
BB Biotech
Switzerland
$25.1M – – –
WA
5
Wasatch Advisors
Utah
$22.6M +$905K +56,040 +3%
Dimensional Fund Advisors
6
Dimensional Fund Advisors
Texas
$16.4M +$393K +24,335 +2%
SC
7
Samlyn Capital
New York
$14.4M +$7.99M +494,918 +64%
Citadel Advisors
8
Citadel Advisors
Florida
$11.9M +$4.36M +269,940 +35%
State Street
9
State Street
Massachusetts
$11.7M +$328K +20,322 +2%
Millennium Management
10
Millennium Management
New York
$10.5M +$6.16M +381,508 +70%
RPAM
11
Rhenman & Partners Asset Management
Sweden
$7.52M +$80.7K +5,000 +0.8%
CS
12
Candriam SCA
Luxembourg
$7.27M +$1.45M +90,000 +16%
Franklin Resources
13
Franklin Resources
California
$7M +$1.96M +121,600 +25%
Northern Trust
14
Northern Trust
Illinois
$6.25M -$86.7K -5,372 -1%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$5.97M +$413K +25,588 +5%
Morgan Stanley
16
Morgan Stanley
New York
$5.82M -$1.09M -67,820 -12%
CCI
17
Columbus Circle Investors
$5.31M -$448K -27,764 -6%
T. Rowe Price Associates
18
T. Rowe Price Associates
Maryland
$4M -$1.46M -90,215 -20%
Norges Bank
19
Norges Bank
Norway
$3.76M – – –
FMBTD
20
First Midwest Bank Trust Division
Illinois
$3.73M +$1.98M +122,756 +60%
Point72 Asset Management
21
Point72 Asset Management
Connecticut
$3.42M -$5.39M -334,114 -53%
GAI
22
General American Investors
New York
$3.42M +$4.84M +299,942 New
Bank of America
23
Bank of America
North Carolina
$3.19M -$6.01M -372,318 -57%
Charles Schwab
24
Charles Schwab
California
$2.91M -$52.4K -3,244 -1%
FCM
25
Farallon Capital Management
California
$2.85M – – –
1
2 3 4 5

ITCI Hedge Fund Activity: Q4 2018 in Review

127 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q4 2018, worth a combined $418M — down 49% from $827M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of ITCI and 15 opened new positions — a net loss of 3 holders — while 46 trimmed existing stakes and 42 added.

The largest buyer was Samlyn Capital, adding an estimated $7.99M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $11M sold.

  • 127 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q4 2018, down from 131 in Q3 2018.
  • Funds reported $418M of Intra-Cellular Therapies Inc. stock for Q4 2018, down 49% quarter-over-quarter.
  • 15 funds opened new Intra-Cellular Therapies Inc. positions in Q4 2018 and 18 closed out, a net change of -3 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q4 2018 was Samlyn Capital, an estimated $7.99M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q4 2018 was Balyasny Asset Management, an estimated $11M sold.

Based on aggregated 13F filings for Q4 2018.